Bayer's Two-Front Strategy: Drug Pipeline Gains Momentum as Supreme Court Weighs Roundup Fate

Bayer argues federal law preempts state claims in Monsanto case, while Asundexian stroke data and Kerendia approval offer a counter-narrative to legal woes.

The German pharmaceutical and agricultural giant finds itself at a crossroads this week, with its legal destiny hanging in the balance before the US Supreme Court while its drug development engine delivers some of the most promising clinical data in years.

Oral arguments began Monday in the case of Monsanto Company v. Durnell, a pivotal moment for the Leverkusen-based group that still faces roughly 65,000 pending lawsuits tied to its $63 billion acquisition of Monsanto in 2018. The central legal question: whether federal pesticide labeling law preempts state-level failure-to-warn claims. Bayer argues it does, and the Trump administration has thrown its weight behind that position, with the Solicitor General filing an amicus brief warning against an "inconsistent patchwork" of state warning requirements.

A ruling is expected by the end of June. But even a favorable outcome would not provide complete relief. While most lawsuits hinge on warning labels — precisely what federal law governs — many contain additional claims that could proceed independently. The Durnell case itself adds a wrinkle: the Missouri plaintiff is relying not on product labeling but on marketing materials from the 1990s and 2000s, potentially limiting the scope of any ruling's impact on this specific case.

A $7.25 Billion Insurance Policy

Bayer has not left everything to the justices. In February, the company announced a $7.25 billion settlement proposal designed to resolve the bulk of current and potential future claims. A Missouri court granted preliminary approval in March, with plaintiffs having until June 4 to opt out. Final confirmation is scheduled for July.

The financial toll is already visible. Bayer has earmarked roughly €5 billion for litigation-related payouts this year, pushing free cash flow into negative territory of between €1.5 billion and €2.5 billion. The stock reflects the tension: trading at €38.50, it sits nearly 22% below the 52-week high of €49.17 reached in February, though it has still climbed about 68% over the past twelve months.

Clinical Wins Offer a Counter-Narrative

While the legal drama unfolds in Washington, Bayer's pharmaceuticals division is delivering results that could reshape the company's long-term story.

In April, the company published full Phase III results from the OCEANIC-STROKE study in the New England Journal of Medicine. The data showed that Asundexian reduced ischemic strokes by 26% compared to placebo, with no increase in bleeding risk. It marks the first successfully completed Phase III trial of a FXIa inhibitor, and the FDA has already granted the drug Fast Track status. Analysts view Asundexian as a serious blockbuster candidate for secondary stroke prevention.

Meanwhile, kidney drug Kerendia (finerenone) is expanding its reach. The European Commission has approved it for a new indication: heart failure with left ventricular ejection fraction of 40% or higher. About half of the roughly 15 million Europeans suffering from heart failure fall into this category. Kerendia generated €829 million in revenue last year, and Bayer projects peak annual sales of €3 billion. A fifth successful Phase III study, FIND-CKD, demonstrated that finerenone also slows disease progression in non-diabetic chronic kidney disease, and Bayer plans to submit those data to regulators.

Cancer drug Nubeqa posted 57% growth to €2.4 billion. Management sees 2026 as the final year of significant headwinds from patent expirations on Xarelto and Eylea.

A CEO Under the Clock

CEO Bill Anderson, who took the helm in mid-2023, promised shareholders he would "significantly contain" the Roundup litigation by the end of 2026. At the most recent annual general meeting, he pointed to "great progress" — citing a stronger drug pipeline and advances in managing the legal legacy. But investors made clear their patience has limits.

The Supreme Court ruling in June will test whether the stock's recent rally rests on solid ground. The July hearing for final settlement approval will reveal just how durable Bayer's parallel strategy really is. Between the justices and the settlement judge, the company needs a clear line drawn under the Roundup saga by year-end — and the clinical pipeline is providing the kind of ammunition that could make the post-litigation story worth waiting for.